Mami Hino has experience in representing the world’s leading technology companies for many years in disputes, litigation, and transactions. Mami’s practice emphasizes invalidity trials and resultant IP High Court appeals, cross-border infringement litigation, strategic patent prosecution, client counseling, and opinions. She collaborates with a variety of clients from heavy machinery companies to consumer product companies, including chemical companies and pharmaceutical companies.
Due to her background as a registered pharmacist, Mami has extensive experience representing innovator pharmaceutical companies to protect their patents, such as filing patent term extension applications, defending their patents in invalidity trials and IP High Court appeals, filing preliminary injunction requests, and/or patent infringement suits against generic drug companies.
Mami studied law at a U.S. law school (J.D.) and practiced as an attorney at a New York law firm that specializes in intellectual property. She can provide foreign clients with Japanese IP advice by utilizing her understanding of the differences between foreign IP practice and Japanese IP practice.
In the United States and other countries, there is a growing awareness and increasing appreciation of the purpose and value of amicus curiae practice as an aid in adjudicative decision-making. The role of an amicus curiae (“friend of the court”) brief in support of a party, or in support of no party, is to supply, voluntarily, the presiding court or other tribunal in cases of controversy with pertinent information, insights, or arguments in a formal, publicly accessible manner. Toward that end, a well-written amicus brief is one that is useful to the decision-maker(s) in calling attention to relevant or material factual or legal aspects of the issue(s) in contention – aspects that the decision-maker(s) or the party-litigants may not have been aware of or able to develop fully.